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Abstract: Adenosine is a ubiquitous signaling molecule, with widespread activity across all organ systems. There is evi-
dence that adenosine regulation is a significant factor in traumatic brain injury (TBI) onset, recovery, and outcome, and a 
growing body of experimental work examining the therapeutic potential of adenosine neuromodulation in the treatment of 
TBI. In the central nervous system (CNS), adenosine (dys)regulation has been demonstrated following TBI, and correlated 
to several TBI pathologies, including impaired cerebral hemodynamics, anaerobic metabolism, and inflammation. In addi-
tion to acute pathologies, adenosine function has been implicated in TBI comorbidities, such as cognitive deficits, psychi-
atric function, and post-traumatic epilepsy. This review presents studies in TBI as well as adenosine-related mechanisms 
in co-morbidities of and unfavorable outcomes resulting from TBI. While the exact role of the adenosine system following 
TBI remains unclear, there is increasing evidence that a thorough understanding of adenosine signaling will be critical to 
the development of diagnostic and therapeutic tools for the treatment of TBI. 
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INTRODUCTION – ADENOSINE IN TBI 
  Adenosine  (Ado)  is  a  signaling  molecule  with  wide-
spread  actions  throughout  the  body.  A  Pubmed  search  for 
adenosine reviews restricted to 2008 revealed over 50 arti-
cles reviewing adenosine physiology, pathology, modulation, 
and therapeutic targets for subjects ranging from cardiovas-
cular, renal, enteric, and sleep function to asthma, inflamma-
tion, and dermal wound healing. In the central nervous sys-
tem (CNS), adenosine (dys)regulation is implicated in cogni-
tion, psychiatric function, Parkinson’s disease, Alzheimer’s 
disease, epilepsy, and hypoxia/ischemia. This review is in-
tended to highlight the role of adenosine acutely following 
TBI as well as the potential adenosine-related mechanisms in 
co-morbidities of and unfavorable outcomes resulting from 
TBI, building on earlier studies [113].  
  The distribution of adenosine receptors makes Ado both 
an attractive target for continuing study and provides a po-
tentially  daunting  complication  for  adenosine-based  treat-
ment  strategies.  There  is  an  extensive  set  of  tools  for  the 
study  of  adenosine,  including  agonists  and  antagonists  of 
varying  selectivity  and  specificity,  transgenic  mice,  and 
functional assays. Several adenosine-related therapeutic can-
didates are either currently available or in clinical trials [11, 
52], potentially easing the regulatory burden for subsequent 
applications.  However,  the  ubiquitous  nature  and  diverse 
effects of adenosine signaling requires particular attention to 
drug delivery and activation, and the potentially significant 
side effect profile. 
  Adenosine  is  a  potent  neuromodulator,  acting  at  CNS 
synapses  to  restrict  synaptic  activity  via  four  known  g-
protein coupled receptor subtypes, reviewed in [11]. Adeno-
sine receptors are found throughout the brain [15], and are  
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implicated in diverse neurological functions and pathologies 
[48]. In addition to its role as a signaling molecule, the nu-
cleoside Ado is an intermediary in a metabolic pathway that 
includes the nucleobase adenine, the nucleotide ATP (a pri-
mary  energy  substrate),  and  the  second  messenger  cyclic 
adenosine monophosphate (cAMP) (Fig. (1)), which further 
highlights the varied consquences of Ado dysregulation. The 
neuroprotective role of Ado is well established in inflamma-
tion, ischemia/reperfusion injury, and asthma [90] as well as 
in diverse CNS diseases [20]. Unlike excitatory and inhibi-
tory amino acids with an “all or none” effect, Ado acts in the 
CNS as a modulator [119], which may be a key factor reduc-
ing negative side effects such as those found with NMDA 
receptor antagonists [57]. 
  Traumatic brain injury is a significant health burden in 
the United States; the US Centers for Disease Control esti-
mated 1.4 million TBIs per year in 2001 [81]. In a recent 
survey of Iraq war veterans, 15% of returning soldiers re-
ported  a  mild  TBI;  of  those,  48%  had  symptoms  of  post-
traumatic stress disorder [65]. Additional lasting effects sig-
nificantly  associated  with  a  brain  injury  are  chronic  pain 
[102], fatigue and other sleep disturbances [141], cognitive 
problems [78], anxiety [98], and epilepsy [23, 122]. While 
these symptoms subside for many patients, they can persist 
for a lifetime of disability [66, 105].  
NEUROPHYSIOLOGY  OF  THE  ADENOSINE  SYS-
TEM 
  The A1 and A2A receptors are widely expressed in brain, 
with  high  adenosine  affinity  (~100nM  [38]),  and  comple-
mentary  actions.  The  A1  receptor  is  a  Gi/Go  coupled  me-
tabotropic  receptor,  acting  to  inhibit  adenylyl  cyclase  and 
cAMP production, with uniform expression throughout the 
CNS [16, 37]. It is generally inhibitory at synapses, activat-
ing K
+ and Cl
- channels and inhibiting P- and N-type voltage 
gated calcium channels. The A2A receptor is a Gs coupled 
metabotropic  receptor,  activating  adenylyl  cyclase  and 
cAMP  production  (Fig.  (2)).  While  RT-PCR  studies  show Adenosine Neuromodulation and Traumatic Brain Injury  Current Neuropharmacology, 2009, Vol. 7, No. 3    229 
expression throughout the brain [37], it is preferentially ex-
pressed  in  the  striatum,  nucleus  accumbens,  and  thalamus 
[118].  A2A  receptors  interact  with  A1  receptors,  forming 
functional heteromers [31], as well as with several excitatory 
receptors, notably the dopamine [8, 44] and glutamate sys-
tems [121, 135]. Free adenosine in the brain (the “tone”) is 
typically in the nanomolar range [11, 83]. Adenosine is in-
creased  locally  to  millimolar  levels  during  low  frequency 
synaptic activity [43], acting primarily via the A1 receptor as 
a presynaptic inhibitor of excitatory amino acid release and 
postsynaptically to maintain hyperpolarization [34]. Adeno-
sine  appears  to  act  as  the  unifying  signaling  molecule  in 
studies of the molecular basis of learning [34]. It acts as an 
autocrine  signaling  molecule  at  the  tetanized  synapse,  en-
hancing synapse strength via A2A receptor activation [4]. It 
acts as a paracrin signal via a calcium wave in the astrocytic 
syncitium,  acting  distant  from  the  tetanized  synapse  to 
achieve heterosynaptic depression by A1 receptor activation 
[58]. In addition to their role at the synapse, astrocytes re-
lease Ado at endothelial cells, causing vasodilation via A2A 
receptor  activation,  which  enhances  local  circulation  and 
provides  the  additional  metabolic  support  rquired  during 
intense synaptic stimulation [61]. 
  The low-affinity (micromolar [38]) A2B and A3 receptors 
are also widely expressed in brain, though at low levels [37]. 
Their low affinity for adenosine makes them likely mediators 
of excessive adenosine signaling, such as occurs in trauma, 
but there is little research on their specific roles. Like the A1 
and A2A receptors, the A2B and A3 receptors have comple-
mentary actions; the A2B receptor is Gs coupled, and the A3 
Gi/Gq coupled (Fig. (2)). Unlike the A1 and A2A receptors, 
their expression seems to be mainly astrocytic. Stimulation 
of the A2B receptor rapidly triggers interleukin-6 production, 
making this a likely step in the inflammatory response fol-
lowing trauma [140]. A2B receptors are upregulated follow-
ing  ischemic  preconditioning,  again  suggesting  a  primary 
role in endogenous neuroprotective mechanisms [149]. The 
role of the A3 receptor is more controversial [10]. Studies 
have shown that A3 receptor activation is protective in astro-
cytes [17]. In neurons, a more complicated response has been 
revealed, with A3 receptor activation protecting CA1 neurons 
during short duration oxygen-glucose deprivation, yet caus-
ing damage during long-duration depriviation [116].  
PATHOLOGY  OF  THE  ADENOSINE  SYSTEM  AF-
TER TBI 
  The study of TBI is unusual in that the invasive proce-
dures  required  to  stabilize  and  monitor  a  severely  injured 
patient have facilitated clinical studies that would be impos-
sible in other injuries or chronic diseases. Intracranial pres-
sure (ICP) has long been recognized as an indicator of TBI 
severity [56, 97]. ICP monitoring is an important component 
of a multi-modal monitoring procedure in the neurological 
intensive care unit [145]. As it requires insertion of a catheter 
into the ventricle, ICP monitoring allows regular monitoring 
of CSF. Consequently, we have an extensive understanding 
of changes to adenosine and its metabolites following human 
TBI. 
Cyclic AMP 
  3'-5'-cyclic adenosine  monophosphate (cAMP) is  a key 
component of the adenosine metabolic pathway (Fig. (2)). 
cAMP is a second messenger regulated by G-protein coupled 
receptors which serve to rapidly couple extracellular signals 
to intracellular responses. cAMP is is modulated by diverse 
extracellular  signals,  including  hormones,  dopamine,  glut-
mate, and adenosine. Current understanding of cAMP dem-
onstrates the functional diversity of cAMP signaling [5] and 
highlights its role in synaptic plasticity [2, 39]. Specificity in 
cAMP signaling may be due to cellular compartmentaliza-
tion  [110,  148],  though  this  is  not  yet  well  understood  in 
brain cells.  
  Early studies of the second messenger cAMP were based 
on the hypothesis that cAMP is a metabolic regulator. Clini-
cal studies show that depth of coma is correlated to reduced 
cAMP  in  CSF,  falling  as  low  as  1.5  nM  during  grade  V 
coma, with a steady improvement correlated to coma depth, 
to nearly normal levels (20 nM) upon reaching grade I [45, 
124]. Of note, in these studies plasma levels of cAMP re-
mained normal (9-19 nM), even when CSF levels were < 6 
nM, suggesting that the CSF cAMP measures reflect changes 
specific  to  the  brain,  and  not  a  systemic  reduction  [45]. 
Regulation of CSF cAMP levels has been demonstrated in 
many neurological diseases. Eight-to-twelve hours following 
cerebral  infarction,  increased  cAMP  has  been  measured 
[100],  but  levels  are  depressed  by  3  days  [24].  Following 
epileptic seizure, depressed cAMP levels were measured for 
3 days [100], and are chronically low in patients with multi-
ple sclerosis [94]. These measurements of cAMP provide a 
valuable diagnostic tool, as well as insight into the evolution 
of brain injury.  
Cerebral Blood Flow 
  Oxygen and glucose are critical to brain function; con-
tinuous cerebral blood flow (CBF) is necessary as there are 
no energy stores in the brain. The mechanisms of CBF and 
metabolism have been described in detail [142]. Autoregula-
tory mechanisms in the brain circulation can compensate for 
minor  or  short  term  disruptions  in  blood  flow,  pressure, 
and/or volume. Brain swelling is a common consequence of 
TBI;  as  the  volume  within  the  intact  skull  is  fixed,  such 
swelling results results in compression of the ventricles (re-
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duction in CSF volume) and vasoconstriction (reduction in 
blood flow). While clinical monitoring of patients with se-
vere head injury has revealed wide fluxuations in CBF, oxy-
gen  demand  remains  consistently  low  [108],  even  during 
hyperperfusion [33]. Kochanek et al. measured CSF levels of 
adenosine and cerebral oxygen use to test the hypothesis that 
adenosine could account for  this uncoupling, as  adenosine 
causes  vasodilation  via A 2A  receptors  on  endothelial  cells, 
and represses synaptic  activity  through the A1 receptor on 
neurons. They found that increased adenosine was associated 
with depressed arterio-jugular venous oxygen difference and 
increased risk of death [32, 73]. Using microdialysis, Bell et 
al. demonstrated increased adenosine and cAMP levels in the 
cortex after TBI during secondary oxygen desaturation, cor-
relating  these  increases  to  increased  glutamate  and  lactate 
[14],  further  supporting  a  role  for  adenosine  release  as  a 
critical mediator of the cerebral response to TBI. 
Cellular Metabolism 
  Closely related to cerebral blood flow is cellular metabo-
lism, the means by which brain cells produce their primary 
energy substrate ATP. The first step is glycolysis, in which 
glucose is converted to pyruvate: 
Glucose + 2NAD
+ + 2ADP + 2Pi >> Pyruvate + 2NADH + 
2H
+ + 2ATP + 2H2O. 
  Under physiologic conditions, pyruvate and NADH be-
come the substrates for aerobic metabolism by the citric acid 
cycle, oxidizing NADH to NAD+ as well as generating ATP. 
Under  anaerobic  conditions,  NAD+  is  replenished  by  the 
enzyme lactate dehydrogenase: 
Pyruvate + NADH
+ + H
+ >> Lactate + NAD
+. 
  Lactic acid is readily measured in the CSF, and a clear 
indicator of hypoxic conditions in the brain. 
  Hypoxia  and  ischemia  are  common  co-morbidities  of 
TBI [29, 55, 67], and their treatment is the focus of signifi-
cant clinical literature [28, 51, 63, 64, 95, 150]. Not all cere-
bral metabolic crisis is due to ischemia however; combined 
PET scans and microdialysis showed significant increases in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Adenosine and metabolites regulated in response to TBI. Compounds in italics are exogenous drugs discussed in the text. 
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the lactate/pyruvate ratio in the absence of ischemia [143], 
suggesting increased anaerobic metabolism.  
  Breakdown of ATP in metabolically stressed tissue is a 
potentially  significant  source  of  adenosine;  clinical  meas-
urements  following  TBI  demonstrate  lasting  alterations  in 
the adenosine metabolic pathway. Cerebralspinal fluid (CSF) 
samples taken following severe TBI show significant eleva-
tions  in  adenosine  in  both  adults  [32]  and  children  [120, 
129].  Further  studies  have  shown  that  components  of  the 
adenosine  metabolic  pathway  including  cAMP,  adenosine, 
inosine, hypoxanthine, and xanthine are all transiently upregu-
lated during secondary hypoxic periods in both clinical [14], 
and  experimental  [13]  settings.  Clinically,  Ado  levels  are 
typically highest at early time points, though late elevations 
(>  72  hours  following  TBI)  have  been  noted  in  children 
[120], and likely reflect the progression of secondary injury. 
Using  microdialysis,  Bell  et  al.  demonstrated  increased 
adenosine and cAMP levels in the cortex after TBI during 
secondary oxygen desaturation, correlating these increases to 
increased  glutamate  and  lactate  [14].  In  rodent  models  of 
fluid  percussion  injury,  transient  decreases  in  ATP  (with 
recovery by 24 hours) followed similar kinetics of adenosine 
increase; however, when FPI was combined with secondary 
ischemia, ATP remained depressed at 24 hours [6]. While 
these studies make it clear that the adenosine system is al-
tered by TBI, it is not yet clear whether this increased adeno-
sine reflects endogenous neuroprotection mechanisms or is a 
byproduct of ATP breakdown. 
MODULATION  OF  ADENOSINE  RECEPTOR  AC-
TIVITY 
  Direct  modulation  of  adenosine  (up  to  30-fold)  in  re-
sponse to stimuli has been measured in multiple model sys-
tems [83]. Neuroprotection by adenosine receptor  modula-
tion has been demonstrated in several model systems, includ-
ing hypoxia/ischemia [123, 133], epilepsy [18, 101], Parkin-
son’s  disease  [27,  69,  130],  inflammation  [26,  60]  among 
others [27, 38, 119]. They play a key role in many organ 
systems, however, and have been the target of several drug 
treatments for respiratory disease [137, 139, 147], cardiovas-
cular disease [40, 111],  and hepatic  injury [12].  While no 
clinically  effective  neuroprotective  strategies  based  on 
adenosine receptor  modulation have yet  emerged,  modula-
tion of adenosine receptor activity has provided insight into 
the diverse roles of adenosine  in neural function and dys-
function.  
Agonist/Antagonist Studies 
  In vivo studies of adenosine receptor modulation in TBI 
have  demonstrated  modest  therapeutic  improvements.  The 
non-selective Ado agonist 2-chloro-adenosine (2CA), active 
at A2B > A1 > A2A receptors (IUPHAR database [59]), has 
been used in several experimental models. Kochanek et al. 
have demonstrated  that  intraparenchymal injection of 2CA 
increases CBF  in the rat brain in a broad, dose-dependent 
and persistent manner [75]. Administration of 2CA by intra-
hippocampal injection after CCI restored CBF, more effec-
tively in moderate injury than in severe injury [74]. By other 
measures, however, the effects of 2CA treatment are mixed. 
Pre-treatment with 2CA by intra-cerebral ventricular (ICV) 
injection  demonstrated  partial  restoration  of  [Mg
2+]  levels, 
and a small, but non-significant, improvement in neuroscore 
at 1 and 7 days following injury [62]. Post-CCI, intrahippo-
campal  injection  of  2CA  resulted  in  improved  wire-grip 
scores but no improvement in memory tasks or hippocampal 
cell survival [138]. Post injury treatment with the A1 receptor 
agonist CCPA improved the CA3 cell count, but had no sig-
nificant  effects  on  learning  and  behavior  measures  [138], 
while  the  A1  receptor  antagonist  DPCPX  and  its  solvent 
DMSO both resulted in increased lesion volume and reduced 
balance beam activity [138]. Together, these results reinforce 
the  role  of  adenosine  receptors  as  neuromodulators,  with 
effects specific to the selected outcome measure. Additional 
studies with longer survival times are also likely to demon-
strate more definitive effects of adenosine receptor antago-
nism and antagonism.  
  Interpretation  of  drug  studies  is  complicated  by  our 
evolving understanding of receptor pharmacology as well as 
different  methods  of  assessing  agonist/antagonist  kinetics. 
Within these limits, relative adenosine affinity must also be 
considered; A1 and A2A receptors have a much higher Ado 
affinity (10 – 100 times greater [38]) than A2B and A3 recep-
tors, so modulation of the A2B and A3 receptors may only 
influence  the  most  extreme  adenosine  response,  and  may 
define the difference between beneficial and harmful adeno-
sine  activity.  The  presence  of  A1/A2A  heteromers  further 
complicates  the  interpretation  of  activation/inhibition  stud-
ies. The use of adenosine receptor knockout mice allows the 
examination of the specific receptor effects without the con-
founding effects of invasive drug delivery methods and non-
specific  vehicle  effects  (eg,  DMSO).  Adenosine  receptor 
knockouts have a relatively normal phenotype, making them 
an attractive tool for the study of adenosine regulation fol-
lowing TBI [49]. Knockout of the A1 receptor leads to lethal 
status  epilepticus  following  cortical  contusion  injury  [76], 
reinforcing the neuroprotective role of the A1 receptor as a 
synaptic inhibitor. Concurrent measurement of cAMP in this 
model would be interesting, as A1 receptor activation inhib-
its adenylyl cyclase and A1 knockout would be expected to 
enhance cAMP production (Fig. (2)), giving some additional 
insight  into  the  causality  of  the  cAMP-adenosine  cycle. 
Knockout of the A2A receptor is neuroprotective in the CCI 
model [87], with improved neuromuscular behavior, reduced 
tunel staining, and reduced glutmate release. Perhaps most 
interestingly, the pro-inflammatory cytokines TNF-α and IL-
1β were significantly decreased by 24 hours following injury 
in the A2A knockout mice when compared to wild-type mice. 
Though the specificity of these effects is still unclear, these 
results further illustrate the complexity of adenosine signal-
ing and the interdepencence of adenosine signaling, neural 
tissue, the immune response, and the cerebrovascular system; 
any therapy affecting one parameter is likely to have an af-
fect on the others. 
Caffeine 
  Caffeine is a well-known stimulant with a primary inhibi-
tory activity at the A1 and A2A receptors. Coffee,  tea, and 
soda are common sources of dietary caffeine, containing 40-
120 mg/serving, and in excess of 200 mg in “energy” drinks. 
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outcome in clinical studies; at 6 months following TBI, ele-
vated  caffeine  was  a  stronger  predictor  of  outcome  than 
Glasgow  Coma  Score  or  alcohol  on  admission  [126].  In 
modeled TBI, acute pre-treatment with  caffeine (50 – 150 
mg/kg) worsens outcome by all measures studied, including 
mortality,  behavior,  edema  and  blood-brain  barrier  break-
down, and peroxidase  activity [3, 86]. In contrast,  chronic 
pre-treatment with caffeine resulted in improvements in neu-
roscore,  edema,  apoptosis,  CSF glutamate, and markers of 
the inflammatory response (CD45, TNF-α, and IL-1) [86]. 
Of note, chronic caffeine treatment resulted in increased A1 
receptor mRNA expression [86]; a corresponding increase in 
A1 receptor expression is likely a significant contributor to 
the protective effects of chronic caffeine.  
  The effects of caffeine are not limited to the adenosine 
receptors. Caffeine stimulates IP-3 receptor mediated intra-
cellular calcium release; calcium activates adenylyl cyclase, 
which catalyzes ATP into cAMP. Mechanical deformation of 
neural  cells  causes  a  significant  acute  rise  in  cytosolic 
[Ca2+] [82, 91, 125]; however, following stretch, it is not 
possible to to elicit this calcium response [146], suggesting 
that acute pre-treatment with caffeine may cause rapid and 
sustained increase in neuronal calcium, disrupting ionic ho-
meostasis, and sensitizing the brain to a subsequent injury. 
The combined actions of caffeine to enhance cAMP produc-
tion via adenylyl cyclase activation may have a role in the 
effects of acute caffeine treatment; however, evidence in the 
literature is contradictory. Clinically, cAMP increases during 
oxygen desaturation after TBI [14], but does not change dur-
ing secondary swelling [73]. In a rodent model of CCI, no 
acute  changes  were  measured  in  cAMP  [13].  In  contrast, 
following lateral fluid percussion injury, not only were sig-
nificant  reductions  in  cAMP  measured,  but  phosphodi-
esterase inhibition with rolipram restored cAMP levels, re-
duced negative histopathological findings, and decreased the 
inflammatory response [7]. While the precise role of caffeine 
in the severity and recovery from TBI remains unknown, its 
wide use and clear effects in modeled TBI make it a potential 
confounding factor in clinical evaluation and treatment. 
ADENOSINE REGULATION 
  Adenosine levels in the brain are typically in the range of 
30-300 nM. Key Ado modulators include 5’-nucleotidases, 
adenosine deaminase (ADA), and adenosine kinase (ADK) 
(Fig.  (2)).  While  neurons  and  glia  both  contribute  to  the 
maintainence of adenosinergic tone, expressing many similar 
enzymes, there is evidence that they respond to stimuli by 
different pathways [110]. Further, regionally distinct expres-
sion and activity of each of these enzymes suggests that the 
adenosine  tone  may  differ  by  region  [112].  Adenosine i n-
volvement in the sleep/wake cycle is well established (recent 
reviews include [80, 96, 132]), and activity of these adeno-
sine modulators in the sleep regions of the brain follow simi-
lar diurnal patterns [92]. Further studies have demonstrated 
the effects of age on adenosine modulator activity, and shown 
that, while ADA does not vary with age, 5’nucleotidases and 
ADK both increase significantly with age [93]. While there 
is  little  direct  study  of  these  adenosine  modulators  in  the 
context of TBI, their rapid and direct influence on the levels 
of adenosine in the brain make them a likely influence on 
outcome after TBI. 
5’-Nucleotidases 
  Located on the cell surface (ecto-) and in the cytosol (cy-
tosolic, endo-), 5’-nucleotidases act to hydrolyze ATP, AMP, 
and ADP to Ado [22]. Two commonly studied nucleotidases 
are  CD39  (also  known  as  apyrase  and  nucleotide  triphos-
phate  diphosphohydrolase)  and  CD73.  CD39  hydrolyzes 
ATP  to  ADP  and  AMP,  while  CD73  hydrolyzes  AMP  to 
Ado. In particular, increases in CD73 function, mRNA, and 
protein have been shown in endothelial monolayers, as early 
as 8 hours following the onset of hypoxia or reperfusion [88, 
90], suggesting that it may be a component of the endoge-
nous  response  leading  to  ischemic  preconditioning  [47]. 
Models  of  pilocarpine-induced  epilepsy  suggest  that  en-
hanced ecto-nucleotidase activity may have a significant role 
in the “silent” phase of epileptogenesis [144]. In vivo studies 
examining  the  cellular  response  to  a  cortical  stab  injury 
(CSI) show a biphasic regulation of CD73: by 4 hours fol-
lowing the CSI, AMP hydrolysis is significantly reduced in 
the region of the stab wound [104], but by 15 days it has 
increased significantly in all regions of the brain considered 
[103]. In contrast, CD39 activity changed little, and only in 
the region of the CSI [104]. 
Adenosine Deaminase 
  Adenosine Deaminase (ADA) catalyzes the conversion of 
Ado to inosine (reviewed in [46]), and can be located either 
in the cytosol or on the extracellular surface of the plasma 
membrane  of  neurons,  glia,  and  endothelial  cells  [30,  99, 
117]. ADA acts rapidly during ischemic events to decrease 
local Ado [109]. As  Ado has  anti-inflammatory properties 
[26, 60], it has been hypothesized  that  inhibition of ADA 
might  increase  abient  Ado,  reducing  inflammation.  The 
ADA inhibitor FR234938 reduced plasma levels of the pro-
inflammatory  cytokine  TNF-α  and  elevated  the  anti-
inflammatory cytokine IL-10 in response to lipopolysaccha-
ride treatment [77]. Further, treatment with the ADA inhibi-
tor  deoxycoformycin  was  protective  following  permanent 
focal ischemia, with a notable reduction in swelling [89]. Of 
interest, colocalization of ADA, the A1 receptor, and the cy-
tokine CD26 (also known as dipeptidyl peptidase IV, DPP-
IV) has been noted in many organs and across species [1, 
16]. CD26 interacts directly with ADA on T-cells [70] as an 
active component of the immune response, and the colocali-
zation of this trio of proteins on endothelial cells [79] may 
have a role in the regulation of the blood-brain barrier fol-
lowing trauma. While the mechanisms of these interactions 
are  not  clear,  this  colocalization  and  conservation  across 
species suggest a causal mechanism. 
Adenosine Kinase 
  In the developing brain, adenosine kinase (ADK) expres-
sion is primarily in the cytosol of neurons [134]. As the brain 
develops, however, ADK expression shifts to the cytosol of 
astrocytes; extracellular Ado  is  taken up by  astrocytes  via 
passive and facilitated diffusion, where it is phosphorylated 
into AMP by ADK. While it has not been studied directly in 
TBI, ADK regulation of adenosine has been implicated in 
many  neurological  disorders  [20].  In  acute  injury  such  as 
ischemia,  ADK  upregulation  is  associated  with  poor  out-
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reviewed in [19]. Chronic diseases (such as epilepsy) have 
been  associated  with  astrogliosis  and  ADK  upregulation 
across multiple models, including kainic acid induced [42], 
kindled  [85],  and  astrogliotic  [84],  reviewed  in  [21].  The 
additive effects of ADA and ADK inhibition [128] may pro-
vide an additional avenue for therapies targeting adenosine 
modulators. 
Adenosine Transport 
  The  third  major  system  for  adenosine  clearance  is  nu-
cleoside transporters, reviewed in [72]. In microdialysis stud-
ies, larger increases in ambient adenosine were measured in 
vivo  in  response  to  treatment  with  uptake  inhibitors  than 
were measured with ADA inhibitors, without the concurrent 
rise in adenosine metabolites inosine and hypoxanthine [9]. 
In a model of cerebral contusion, treatment with the transport 
inhibitor propentofylline increased expression of the neuro-
protective  peptide  basic  fibroblast  growth  factor  [25].  As 
ethanol is a common factor in TBI, a potential additive role 
of adenosine in the cardiovascular response was measured in 
a  swine  model  of  TBI;  however,  no  significant  protection 
was  measured  with  adenosine  transport  inhibition  [41]. 
Adenosine uptake inhibition remains an untapped source of 
potential neurprotective strategies [106]. 
ADENOSINE  REGULATION  AND  TBI  CO-MORBI-
DITIES 
  While many TBI survivors regain gross motor and men-
tal  functions,  comorbidities  often  remain  throughout  life. 
Studies  following  mild  and  moderate  TBI  survivors  show 
improvements in community integration, cognitive and neu-
ropsychiatric  measures  over  6-12  months  [107],  5  years 
[136],  and  22  years  [105].  However,  impairments  persist, 
and there is significant opportunity for therapeutic interven-
tion. Chronic pain is a common result of TBI, even after mild 
injury [102]. Adenosine modulation has been widely impli-
cated  in  inflammation  [26,  53,  60]  and  analgesia  [38,  72, 
127]. Anxiety is one of many neuropsychiatric comorbidities 
of TBI [98], with clear correlates to adenosine dysregulation 
[35, 54, 68]. Post traumatic epilepsy has a long latency, often 
decades, and is particularly common following severe injury 
in both pediatric [131] and adult [50] populations. Even in 
individuals without clinical seizure manifestations, epilepti-
form  activity  has  been  reported  [122].  In  an  A1  receptor 
knockout  mouse,  TBI  led  to  lethal  status  epilepticus  [76], 
suggesting a clear role for the A1 receptor in seizure suppres-
sion. To date, two models of spontaneous seizure develop-
ment following lateral fluid percussion injury (LFPI) have 
been published, with different characteristics. D’Ambrosio et 
al.  reported  rapid  onset  of  high  frequency,  short  duration 
cortical seizure activity, accompanied by generally mild be-
havior manifestations within the first 8 weeks of (1-2 on a 
the 1-5 Racine scale)[36]. Kharatishvili et al. report a latency 
of 2-12 months before seizure onset of seizures, similar to 
the latency observed clinically following TBI, with seizure 
activity lasting nearly two minutes [71]. Further studies im-
plicate adenosine dysregulation in epileptogenesis and epi-
lepsy, reviewed in [21]. Taken together, these results suggest 
that adenosine modulation a source of therapeutic potential 
across the spectrum of traumatic brain injury and recovery.  
CONCLUSION 
  There is strong evidence that adenosine (dys)regulation 
plays a role in the brain following TBI. It is still not clear 
whether Ado is an endognous neuroprotective measure or a 
byproduct of stressed cellular metabolism; the truth is likely 
in  between,  and  linked  to  injury  severity.  Current  studies 
highlight the potential of adenosine to act in both protective 
and detrimental pathways; the multi-factoral pathologies of 
TBI  and  effects  of  adenosine  signaling  may  mean  that 
adenosine is not a practical target for neuroprotective thera-
pies following TBI. Whether the adenosine system emerges 
as a neuroprotective target, it is clear that adenosine has a 
role in the evolution of neural recovery after traumatic brain 
injury, and a thorough understanding of its influences in the 
CNS will be  critical in the development of diagnostic and 
therapeutic tools. 
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2CA  =  2-Chloroadenosine 
Ado  =  Adenosine 
ADA  =  Adenosine Deaminase 
ADK  =  Adenosine Kinase 
ADP  =  Adenosine Diphosphate 
AMP  =  Adenosine Monophosphate 
ATP  =  Adenosine Triphosphate 
cAMP  =  Cyclic Adenosine Monophosphate 
CCI  =  Cortical Contusion Injury 
CCPA  =  2-Chloro-N(6)-Cyclopentyladenosine 
CNS  =  Central Nervous System 
CSF  =  Cerebral Spinal Fluid 
CSI  =  Cortical Stab Injury 
DMSO  =  Dimethyl Sulfoxide 
DPP-IV  =  Dipeptidyl Peptidase IV 
ICV  =  Intra-Cerebroventricular 
LFPI  =  Lateral Fluid Percussion Injury 
NMDA  =  N-methyl-D-aspartic acid 
TBI  =  Traumatic Brain Injury 
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